Vlp Therapeutics Raises $21M Series A-1 For Cancer Treatment Vaccine, Infectious Diseases Vaccine R&D
Vlp Therapeutics Raises $21M Series A-1 For Cancer Treatment Vaccine, Infectious Diseases Vaccine R&D
12/27/21, 7:23 AM
Location
Money raised
$21 million
Round Type
series a
US-based biotech company VLP Therapeutics, Inc. (VLPT) announced on December 27 that it has signed an agreement for an investment of US$21 million in a Series A-1 round from six investors, consisting of two new investors: Nobelpharma Co., Ltd. and MUFG Bank, Ltd., and four existing investors: Sojitz Corporation, MIYAKO Capital Co., Ltd., Mr. Robert G
Company Info
Location
gaithersburg, maryland, united states
Additional Info
VLP Therapeutics, Inc. (VLPT), co-founded in 2013 by Drs. Wataru Akahata, Ryuji Ueno, and Sachiko Kuno, is a Gaithersburg, MD-based biotech company with a mission to address unmet medical needs worldwide and expand the frontiers of vaccine treatment. Led by CEO Akahata VLPT is currently engaged in research and development of a cancer treatment vaccine as well as prophylactic vaccines against malaria, dengue, etc. using VLPT's proprietary platform technologies.
[https://vlptherapeutics.com/]